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In vivo pieces of the PP2A onco-puzzle fallen into place
Bob Meeusen and Veerle Janssens
Although kinases have hijacked the scene for 
several decades now in the battle against cancer, evidence 
has accumulated that phosphatases play equally important 
roles, by putting the brakes on hyperactivated oncogenic 
signaling associated with this disease. Since a long 
time, a major Ser/Thr-specific phosphatase, Protein 
Phosphatase 2A (PP2A), has been attributed important 
tumor suppressive properties, but clear in vivo evidence 
to sustain this notion was lacking. Recent work on the 
occurrence of spontaneous tumor formation in two 
independent PP2A-deficient mouse models finally filled 
this knowledge gap.
PP2A enzymes constitute a large family of >90 
holoenzymes, each slightly or majorly structurally 
different, and hence, being differently regulated or 
harboring different functions [1]. Many PP2A complexes 
counteract signaling pathways driving growth, survival or 
protein synthesis, and are intrinsic regulators of diverse 
cell cycle checkpoints, contributing to their tumor 
suppressive roles in cells [1]. The nearly twenty-year-
old suspicion that ‘PP2A’ represents an important tumor 
suppressor stems from its targeting by chemical tumor 
promotors, such as okadaic acid (OA), and by specific 
viral oncoproteins, such as SV40 and polyoma virus 
small t [1], which inhibit PP2A activity through a direct 
interaction with the catalytic C subunit (for OA), or with 
the scaffolding Aα subunit (for small t). In a subsequent 
effort to define the minimal genetic perturbations required 
for human epithelial cell transformation, it was found that 
expression of telomerase catalytic subunit (hTERT) and 
inhibition of tumor suppressors p53 and pRb (typically 
by SV40 large T) suffice for cell immortalization, while 
additional expression of an activated oncogene (e.g. 
H-RasV12) and inhibition of PP2A (typically by SV40 
small t) are required to achieve full transformation [2]. 
It was further demonstrated that 50% suppression of 
PP2A Aα subunit or suppression of three PP2A regulatory 
B-type subunits (B56/B’α, B56/B’γ and B72/B”α1) 
could partially replace SV40 small t expression in cell 
transformation, while suppression of the PP2A C subunit 
or of the cellular PP2A activator PTPA had a much more 
substantial impact [3,4]. Hence, it was concluded that 
more than one tumor suppressive PP2A complex might 
need to be impaired to allow for full transformation.
A recent study by Sents et al. has now provided in 
vivo evidence to sustain the suspected importance of PP2A 
dysfunction in tumor initiation and/or progression [5]. 
In PTPA gene-trapped mice, still showing residual 
PTPA expression because of the hypomorphic nature of 
the PTPAgt allele, overall PP2A activity and C subunit 
methylation were reduced, while a selective decrease in 
activity of B56/B’ subunit-containing holoenzymes was 
revealed (B56/B’γ and B56/B’ε were tested) and activity 
of B55/B subunit-containing holoenzymes remained 
unaffected (only B55/Bα was tested). Interestingly, 
these mice exhibited higher rates of spontaneous tumor 
formation than wild-type mice. The observed neoplasms 
were mainly hematologic malignancies and sporadically, 
hepatocellular adeno(carcino)mas. Although not identical 
throughout tumor samples, probably due to the random 
nature of the oncogenic event, activation of diverse 
oncogenic pathways was observed, including an increase 
in c-Myc phosphorylation, and in expression of β-catenin 
(Wnt signaling) and Gli-1 (Hedgehog signaling), all 
oncogenes known from cellular studies to be suppressed by 
B56/B’-type of PP2A holoenzymes. Importantly, analysis 
of cBioportal and COSMIC cancer databases demonstrated 
a high frequency (up to 70%) of heterozygous loss or 
monoallelic loss-of-function mutation of the PTPA-
encoding gene PPP2R4 in a strikingly large set of cancers. 
In some cases, this correlated with significantly decreased 
overall patient survival, further underscoring the clinical 
importance of PPP2R4 heterozygous loss or mutation 
as a novel high-penetrance genetic mechanism of PP2A 
inactivation. Together, these data established PPP2R4 as 
a novel obligate haploinsufficient tumor suppressor gene 
[5].
Although the former study seems to confirm that 
likely more than one PP2A holoenzyme needs to be 
functionally disturbed to achieve abolishment of the tumor 
suppressor function of PP2A, another recent study by 
Lambrecht et al. convincingly demonstrated that even the 
lack of a single PP2A regulatory B56/B’-type subunit can 
promote spontaneous tumorigenesis in vivo [6]. Indeed, 
Ppp2r5d knockout mice, devoid of the PP2A B56/B’δ 
subunit in all tissues, appeared prone to spontaneous 
development of diverse cancer types, including 
hematologic malignancies, and much more surprisingly, 
hepatocellular carcinomas (HCC). In the oldest age group 
of the knockout mice, HCC incidence reached nearly 60% 
and could not be linked to increased liver inflammation or 
steatosis, as nearly 70% of the tumors arose in a normal 
liver context. All HCCs examined showed increased 
c-Myc Ser62 phosphorylation, as well as GSK-3β Ser9 
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phosphorylation, the latter being also found in the 
healthy knockout livers. Thus, it was proposed that loss 
of PP2A-B56/B’δ-mediated dephosphorylation of GSK-
3β predisposed for increased c-Myc oncogenicity upon 
fortuitous Ser62 phosphorylation by preventing c-Myc 
degradation. Surprisingly, no obvious clinical evidence 
was found for direct genetic inactivation of PPP2R5D in 
human HCCs or other cancer types, feeding the authors’ 
hypothesis that impairment of PP2A-B56/B’δ function 
may largely occur through indirect mechanisms in human 
cancers, e.g. through specific mutations in PPP2R1A, 
encoding the Aα subunit [7].
In conclusion, two recent mouse genetics studies 
[5,6] eventually provided firm in vivo evidence to sustain 
the tumor suppressive role of PP2A-B56/B’ holoenzymes, 
and particularly of the PP2A-B56/B’δ complex. This paves 
the way for the full clinical development of the PP2A 
status in tumors as prognostic or predictive markers, and 
for the exploitation of dysfunctional PP2A as a promising 
new target for reactivation therapies [8].
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Figure 1: Downregulation of specific PP2A subunits or PP2A regulators results in human epithelial cell transformation 
in vitro, or spontaneous tumorigenesis in vivo – highlighting the major importance of PP2A dysfunction in tumor 
initiation and/or progression.
